Methotrexate 25mg/mL; soln for IV, IM, intra-arterial, or intrathecal administration after dilution; preservative-free. Non-metastatic osteosarcoma in patients who have undergone surgical resection or ...
FDA final approval confirms therapeutic equivalence to Hospira’s methotrexate injection USP at identical strengths and vial presentations, enabling market entry via the abbreviated generic pathway.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results